DCTH Delcath Systems, Inc. - Common Stock
NASDAQ · Health Care · View on SEC EDGAR ↗ close Oct 2, 2026 10-K/10-Q Aug 6, 2026
$15.13
· of 52w range
· above low
· to high
$8.1252w low
$17.4252w high
Market Cap (MRQ)
$524M
P/E (TTM)
1513.0
EPS (TTM)
$0.01
Revenue (TTM)
$95M
your badges
52W Range
$8–$17
Analyst Rating
BUY
Price Target
$24
P/E
1513.0
ROE
0.47%
Net Profit Margin
0.56%
Your badge strip is empty — pin a metric anywhere on this page.
DCTH Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range
Price
$15.13
Market Cap (MRQ)
$524M
P/E (TTM)
1513.0
EPS (TTM)
$0.01
Revenue (TTM)
$95M
ROE (TTM)
0.47%
52W Range
$8–$17
DCTH Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view
range
bars
Bar granularity adapts to the selected period — hover the chart to see open/high/low/close for a bar.
Stock splits
| Ex-date | Split | Type |
|---|---|---|
| Dec. 24, 2019 | 1-for-700 | Reverse |
About Delcath Systems, Inc. - Common Stock Company overview from Wikipedia
Delcath Systems, Inc. (NASDAQ: DCTH) is a publicly traded specialty pharmaceutical and medical device company, that develops percutaneous perfusion technologies for the targeted administration of high-dose chemotherapeutic agents to specific organs or regions of the body. Based in Queensbury, New York, the company has an intellectual property portfolio consisting of 28 patents worldwide. Delcath's Percutaneous Hepatic Perfusion (PHP) is currently undergoing Phase II and Phase III trials against tumors in the liver. Delcath has a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute and has received Fast Track and a Special Protocol Assessment from the Food and Drug Administration for its use of melphalan in treating unresectable liver tumors. PHP, also known as the Delcath System, is tested for the treatment of metastatic melanoma in the liver and for primary liver cancer and metastatic hepatic malignancies from neuroendocrine cancers and adenocarcinomas, as well as patients with melanoma who previously received isolated perfusion. Chemotherapy is usually delivered intravenously, although a number of agents can be administered orally (e.g. specialty drugs, melphalan (trade name Alkeran), busulfan, capecitabine).
## Phase III melanoma trial enrolling
University of Pittsburgh Medical Center
National Cancer Institute in Bethesda, Maryland
Albany Medical Center in Albany, New York
John Wayne Cancer Center in Santa Monica, California
Moffitt Cancer Center in Tampa, Florida
Morristown Memorial Hospital in Morristown, New Jersey
Providence Cancer Center in Portland, Oregon
St. Luke's Cancer Center of Bethlehem, Pennsylvania
Swedish Medical Center in Englewood, Colorado
University of Maryland Medical Center in Baltimore, Maryland
University of Texas Medical Branch in Galveston, Texas
Source: Wikipedia, CC BY-SA 4.0 · View on Wikipedia ↗
sectorHealth Care
industryHealth Care
employees156
countryUS
10-Year Performance Revenue, net income, margins and EPS trends
Revenue$85M2016-12-31 → 2025-12-31
EPS$0.072017-12-31 → 2025-12-31
Free Cash Flow$21M2018-12-31 → 2025-12-31
Net margin0.56%2022-12-31 → 2025-12-31
Valuation & Ratios
Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?
| Metric | 5Y trend | DCTH | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| P/E (TTM) | 1513.05Y avg ≈25.4 | ≈25.4 | · | · | |
| P/S (TTM) | 5.55Y avg ≈17.7 | ≈17.7 | 3.7 | Overvalued | |
| P/B (MRQ) | 4.35Y avg ≈3.0 | ≈3.0 | 3.4 | Overvalued | |
| Price / FCF (TTM) | 29.95Y avg ≈-2.2 | ≈-2.2 | · | · | |
| Price / Cash Flow (TTM) | 26.85Y avg ≈-2.5 | ≈-2.5 | 18.5 | Undervalued | |
| Price / Tangible Book | 4.75Y avg ≈5.0 | ≈5.0 | · | · |
Peer median is calculated on a standardized basis per metric and may not always match the TTM/MRQ basis shown for this stock.
Profitability Gross, operating and net margins; ROE, ROA, ROIC
| Metric | 5Y trend | DCTH | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Gross Margin (TTM) | 87.1%5Y avg ≈78.4% | ≈78.4% | 73.6% | Top tier | |
| Operating Margin (TTM) | -1.9%5Y avg ≈-781.7% | ≈-781.7% | -8.2% | Top tier | |
| EBITDA Margin | 0.77%5Y avg ≈-781.7% | ≈-781.7% | -5.0% | Top tier | |
| Pretax Margin (TTM) | 1.4%5Y avg ≈-929.6% | ≈-929.6% | -11.3% | Top tier | |
| Net Profit Margin (TTM) | 0.56%5Y avg ≈-929.8% | ≈-929.8% | -13.1% | Top tier | |
| ROA (TTM) | 0.42%5Y avg ≈-86.2% | ≈-86.2% | -16.0% | Top tier | |
| ROE (TTM) | 0.47%5Y avg ≈27.9% | ≈27.9% | -25.7% | Top tier | |
| ROIC | 0.46%5Y avg ≈22.6% | ≈22.6% | -23.7% | Top tier |
Financial Health Debt, liquidity, solvency — balance sheet strength
| Metric | 5Y trend | DCTH | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Current Ratio (MRQ) | 9.85Y avg ≈6.3 | ≈6.3 | 3.5 | Strong liquidity | |
| Quick Ratio | 5.05Y avg ≈3.5 | ≈3.5 | 2.2 | Strong liquidity |
Growth Revenue, EPS and net income growth: YoY, 3Y CAGR, 5Y CAGR
| Metric | 5Y trend | DCTH | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Revenue YoY | 129.1%5Y avg ≈445.8% | ≈445.8% | · | · | |
| Revenue CAGR 3Y | 215.3% | · | · | · |
Capital Efficiency Asset turnover, inventory turnover, receivables turnover
| Metric | 5Y trend | DCTH | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Asset Turnover | 0.95Y avg ≈0.4 | ≈0.4 | 0.8 | In line | |
| Inventory Turnover | 1.45Y avg ≈0.8 | ≈0.8 | 1.7 | Weak | |
| Receivables Turnover | 7.55Y avg ≈8.6 | ≈8.6 | 7.3 | Top tier | |
| Revenue / Employee | ≈$546.4K | · | · | · |
value · ≈ 5Y avg · industry median · verdict relative to median
Earnings History EPS actual vs estimate, surprise %, beat rate, next earnings date
Avg Surprise
88.6%
Next Report
Nov 02, 2026
| Period | Report | EPS Actual | EPS Est | Surprise |
|---|---|---|---|---|
| June 30, 2026 | Aug 10, 2026 | $0.07 | $-0.09 | 176.3% |
| March 31, 2026 | May 12, 2026 | $-0.03 | $-0.09 | 66.1% |
| Dec. 31, 2025 | $-0.05 | $-0.06 | 20.5% | |
| Sept. 30, 2025 | $0.02 | $0.02 | -2.0% | |
| June 30, 2025 | $0.07 | $0.03 | 174.5% | |
| March 31, 2025 | $0.03 | $0.02 | 96.1% |
Full Fundamentals All metrics by year — income statement, balance sheet, cash flow
Income Statement
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $85M | $37M | $2M | $3M | $4M | · | · | · | $3M | $2M | $2M | $1M | |
| Cost of Revenue | $12M | $6M | $635.0K | $686.0K | $671.0K | $640.0K | $719.0K | $1M | $701.0K | $550.0K | $462.0K | $291.0K | |
| Gross Profit | $73M | $31M | $1M | $2M | $3M | $1M | $861.0K | $2M | $2M | $1M | $1M | $778.0K | |
| R&D Expense | $29M | $14M | $18M | $19M | $14M | $11M | $9M | $20M | $10M | $8M | $6M | $4M | |
| SG&A Expense | $44M | $30M | $22M | $17M | $14M | $11M | $11M | $10M | $10M | $9M | $10M | $16M | |
| Operating Expenses | $73M | $43M | $40M | $36M | $27M | $22M | $21M | $29M | $20M | $18M | $16M | $20M | |
| Operating Income | $660.0K | $-12M | $-38M | $-34M | $-25M | $-21M | $-20M | $-27M | $-18M | $-16M | $-15M | $-19M | |
| Interest Expense | · | · | · | · | · | · | · | · | $22M | $14M | $67.0K | · | |
| Interest Income | · | · | · | · | · | · | · | · | · | $17.0K | $9.0K | $5.0K | |
| Other Non-op | $-70.0K | $-30.0K | $-59.0K | $30.0K | $68.0K | $154.0K | $2.0K | $51.0K | $-41.0K | $17.0K | $9.0K | $-24.0K | |
| Pretax Income | $4M | $-26M | $-48M | $-37M | $-26M | $-24M | $-9M | $-19M | $-45M | $-18M | $-15M | $-17M | |
| Income Tax | $810.0K | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
| Net Income | $3M | $-26M | $-48M | $-37M | $-26M | $-24M | $-9M | $-19M | $-45M | $-18M | $-15M | $-17M | |
| EPS (Basic) | $0.08 | $-0.93 | $-2.94 | $-4.12 | $-3.59 | $-8.35 | $-342.83 | $-0.72 | $-3250.00 | · | $-0.91 | $-1.84 | |
| EPS (Diluted) | $0.07 | $-0.93 | $-2.94 | $-4.12 | $-3.59 | $-8.35 | $-342.83 | $-0.72 | $-3250.00 | · | $-0.91 | $-1.84 | |
| Shares (Basic) | 35,821,157 | 28,511,393 | 16,229,931 | 8,864,615 | 7,145,754 | 2,897,827 | 25,900 | 26,705,375 | 14,039 | · | 16,161,687 | 9,452,050 | |
| Shares (Diluted) | 39,919,557 | 28,511,393 | 16,229,931 | 8,864,615 | 7,145,754 | 2,897,827 | 25,900 | 26,705,375 | 14,039 | · | 16,161,687 | 9,452,050 | |
| EBITDA | $660.0K | $-12M | $-38M | $-34M | $-25M | $-21M | $-20M | $-27M | · | · | $-15M | $-19M |
Balance Sheet
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $43M | $32M | $13M | $8M | $23M | $29M | $10M | $3M | $4M | $4M | $13M | $20M | |
| Receivables | $12M | $11M | $241.0K | $366.0K | $44.0K | $57.0K | $21.0K | $585.0K | $317.0K | $403.0K | $277.0K | $174.0K | |
| Inventory | $10M | $7M | $3M | $2M | $1M | $855.0K | $654.0K | $858.0K | $1M | $660.0K | $757.0K | $349.0K | |
| Prepaid Expense | $6M | $3M | $1M | $2M | $3M | $3M | $2M | $898.0K | $700.0K | $698.0K | $960.0K | $974.0K | |
| Other Current Assets | · | · | · | · | · | · | · | · | · | · | · | $222.0K | |
| Current Assets | $120M | $74M | $37M | $16M | $31M | $32M | $13M | $6M | $8M | $34M | $15M | $22M | |
| PP&E (Net) | $3M | $2M | $1M | $1M | $1M | $1M | $735.0K | $925.0K | $1M | $1M | $1M | $2M | |
| PP&E (Gross) | $8M | $7M | $6M | $6M | $6M | $6M | $5M | $5M | $5M | $5M | $5M | $6M | |
| Accum. Depreciation | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $4M | $4M | $4M | $4M | $4M | |
| Total Assets | $124M | $77M | $39M | $18M | $33M | $35M | $14M | $7M | $9M | $35M | $16M | $24M | |
| Accounts Payable | $3M | $961.0K | $1M | $2M | $638.0K | $2M | $5M | $8M | $4M | $594.0K | $284.0K | $748.0K | |
| Accrued Liabilities | $8M | $5M | $5M | $5M | $4M | $5M | $7M | $8M | $3M | $3M | $2M | $4M | |
| Current Liabilities | $11M | $6M | $16M | $15M | $6M | $10M | $16M | $18M | $8M | $36M | $6M | $5M | |
| Capital Leases | $835.0K | $933.0K | $0 | · | $207.0K | $450.0K | $197.0K | $0 | · | · | · | · | |
| Other Non-current Liabilities | $628.0K | $766.0K | $840.0K | $1M | $207.0K | · | $0 | $628.0K | $395.0K | $604.0K | $820.0K | $1M | |
| Total Liabilities | $12M | $8M | $23M | $24M | $21M | $13M | $21M | $22M | $8M | $37M | $7M | $6M | |
| Long-term Debt | · | $0 | $10M | $16M | · | · | · | · | · | · | · | · | |
| Common Stock | $347.0K | $331.0K | $228.0K | $100.0K | $79.0K | $60.0K | $1.0K | $0 | $2.0K | $0 | $14.0K | $97.0K | |
| Paid-in Capital | $639M | $600M | $521M | $452M | $433M | $417M | $365M | $329M | $326M | $278M | $270M | $265M | |
| Retained Earnings | $-529M | $-532M | $-505M | $-457M | $-421M | $-395M | $-371M | $-344M | $-325M | $-279M | $-261M | $-247M | |
| Treasury Stock | · | · | · | · | · | · | · | $0 | $51.0K | $51.0K | $51.0K | $51.0K | |
| AOCI | $575.0K | $82.0K | $135.0K | $-83.0K | $18.0K | $-104.0K | $28.0K | $50.0K | $42.0K | $-41.0K | $-8.0K | $20.0K | |
| Stockholders' Equity | $111M | $69M | $16M | $-6M | $12M | $22M | $-6M | $-15M | $678.0K | $-1M | $9M | $18M | |
| Liabilities + Equity | $124M | $77M | $39M | $18M | $33M | $35M | $14M | $7M | $9M | $35M | $16M | $24M | |
| Shares Outstanding | 34,691,671 | 33,061,002 | 22,761,554 | 10,046,571 | 7,906,728 | 5,996,101 | 67,091 | 14,715 | 228,139 | 11,750 | 1,360,239 | 9,708,841 |
Cash Flow
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Deferred Tax | $0 | $0 | · | · | · | · | · | · | · | · | · | · | |
| Operating Cash Flow | $23M | $-19M | $-31M | $-25M | $-23M | $-23M | $-24M | $-15M | $-15M | $-14M | $-16M | $-16M | |
| CapEx | $2M | $559.0K | $58.0K | $209.0K | $143.0K | $782.0K | $24.0K | $76.0K | $524.0K | $258.0K | $170.0K | $44.0K | |
| Investing Cash Flow | $-27M | $-981.0K | $-20M | $-209.0K | $-143.0K | $-782.0K | $-24.0K | $-76.0K | $-524.0K | · | · | · | |
| Net Debt Issued | · | $-11M | $-6M | · | · | · | · | · | · | · | · | · | |
| Stock Issued | $481.0K | $250.0K | $123.0K | $0 | $2M | $230.0K | $0 | $11M | · | · | · | · | |
| Stock Repurchased | $6M | $0 | · | · | · | · | · | · | · | · | · | · | |
| Net Stock Activity | $-6M | $250.0K | $123.0K | · | $2M | $230.0K | $0 | · | · | · | · | · | |
| Financing Cash Flow | $15M | $39M | $52M | $10M | $21M | $42M | $30M | $13M | $-11M | · | · | · | |
| Net Change in Cash | $11M | $20M | $874.0K | $-15M | $-2M | $19M | $7M | $-2M | $-26M | $-8M | $-8M | $-11M | |
| Taxes Paid | $2M | $0 | · | · | · | · | · | · | · | · | · | · | |
| Free Cash Flow | $21M | $-19M | $-31M | $-25M | $-23M | $-24M | $-24M | $-15M | · | · | $-17M | $-16M |
Profitability
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 86.2% | 83.4% | 69.2% | 74.8% | · | · | · | · | · | · | 73.6% | 72.8% | |
| Operating Margin | 0.77% | -33.4% | -1849.0% | -1245.0% | · | · | · | · | · | · | -870.6% | -1805.8% | |
| Net Margin | 3.2% | -70.9% | -2308.9% | -1342.7% | · | · | · | · | · | · | -841.7% | -1625.9% | |
| Pretax Margin | 4.1% | -70.9% | -2308.9% | -1342.7% | · | · | · | · | · | · | -841.7% | · | |
| EBITDA Margin | 0.77% | -33.4% | -1849.0% | -1245.0% | · | · | · | · | · | · | -870.6% | -1805.8% | |
| ROA | 2.7% | -45.8% | -168.8% | -143.2% | -75.7% | -98.9% | -84.3% | -244.4% | · | · | -74.5% | -57.1% | |
| ROE | 2.5% | -68.2% | -235.5% | 657.5% | -216.7% | -190.6% | 70.5% | 194.1% | · | · | -109.9% | -72.0% | |
| ROIC | 0.46% | -18.1% | -242.0% | 577.8% | -205.3% | -96.5% | 313.2% | · | · | · | -176.8% | · |
Liquidity & Solvency
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 10.9 | 12.0 | 2.3 | 1.1 | 5.2 | 3.2 | 0.8 | 0.3 | · | · | 2.3 | 4.8 | |
| Quick Ratio | 5.0 | 7.0 | 0.8 | 0.5 | 3.8 | 2.9 | 0.6 | 0.2 | · | · | 2.0 | 4.5 |
Efficiency
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.9 | 0.6 | 0.1 | 0.1 | · | · | · | · | · | · | 0.1 | 0.0 | |
| Inventory Turnover | 1.4 | 1.2 | 0.2 | 0.4 | 0.6 | 0.8 | 1.0 | 1.0 | · | · | 0.8 | 0.5 | |
| Receivables Turnover | 7.5 | 6.7 | 6.8 | 13.3 | · | · | · | · | · | · | 7.7 | 4.1 |
Per Share
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $3.21 | $2.08 | $0.69 | $-0.74 | $1.51 | $3.68 | $-94.75 | $-1.46 | · | · | $0.40 | $1.87 | |
| Revenue / Share | $2.14 | $1.30 | $0.13 | $0.31 | · | · | · | · | · | · | $0.11 | $0.11 | |
| Cash Flow / Share | $0.56 | $-0.66 | $-1.93 | $-2.81 | · | $-7.89 | · | $-0.55 | · | · | $-1.02 | $-1.65 | |
| Cash / Share | $1.25 | $0.98 | $0.56 | $0.97 | $2.88 | $4.77 | $149.08 | $0.25 | · | · | $0.58 | $2.11 | |
| EPS (TTM) | $0.07 | $-0.93 | $-2.94 | $-4.12 | $-3.59 | $-8.35 | $-342.83 | $-0.72 | $-3250.00 | · | $-0.91 | $-1.84 |
Growth Rates
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 129.1% | 1701.7% | -24.1% | -23.5% | · | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 215.3% | 118.7% | · | · | · | · | · | · | · | · | · | · |
Valuation (TTM)
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $85M | $37M | $2M | $3M | $4M | $3M | $3M | $3M | $3M | $2M | $2M | $1M | |
| Net Income TTM | $3M | $-26M | $-48M | $-37M | $-26M | $-24M | $-9M | $-19M | $-45M | $-18M | $-15M | $-17M | |
| Market Cap | $350M | $398M | $95M | $28M | $61M | $107M | $1M | $2.01B | · | · | · | · | |
| P/E | 144.3 | -12.9 | -1.4 | -0.9 | -2.2 | -2.1 | -0.1 | -272.2 | · | · | · | · | |
| P/S | 4.1 | 10.7 | 45.9 | 10.5 | 17.2 | 34.8 | 0.5 | 649.3 | · | · | · | · | |
| P/B | 3.2 | 5.8 | 6.0 | -4.9 | 5.1 | 4.9 | -0.2 | -134.2 | · | · | · | · | |
| P / Tangible Book | 3.2 | 5.8 | 6.0 | · | 5.1 | 4.9 | · | · | · | · | · | · | |
| P / Cash Flow | 15.6 | -21.3 | -3.0 | -1.1 | -2.7 | -4.7 | -0.1 | -136.1 | · | · | · | · | |
| P / FCF | 16.7 | -20.7 | -3.0 | -1.1 | -2.7 | -4.5 | -0.1 | -135.4 | · | · | · | · | |
| Earnings Yield | 0.69% | -7.7% | -70.7% | -114.4% | -46.3% | -46.6% | -1613.3% | -0.37% | · | · | · | · |
Income Statement
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $29M | $25M | $21M | $21M | $24M | $20M | $15M | $11M | $8M | $3M | $539.0K | $434.0K | $495.0K | $597.0K | $638.0K | $906.0K | |
| Cost of Revenue | $3M | $4M | $3M | $3M | $3M | $3M | $2M | $2M | $2M | $903.0K | $171.0K | $133.0K | $150.0K | $181.0K | $238.0K | $235.0K | |
| Gross Profit | $26M | $21M | $18M | $18M | $21M | $17M | $13M | $10M | $6M | $2M | $368.0K | $301.0K | $345.0K | $416.0K | $400.0K | $671.0K | |
| R&D Expense | $10M | $10M | $9M | $8M | $7M | $5M | $3M | $4M | $3M | $4M | $5M | $5M | $4M | $5M | $4M | $4M | |
| SG&A Expense | $13M | $13M | $11M | $10M | $11M | $11M | $7M | $7M | $7M | $9M | $7M | $6M | $5M | $4M | $4M | $5M | |
| Operating Expenses | $24M | $23M | $20M | $18M | $18M | $16M | $10M | $11M | $10M | $13M | $12M | $11M | $8M | $9M | $8M | $9M | |
| Operating Income | $2M | $-2M | $-2M | $-388.0K | $3M | $642.0K | $3M | $-1M | $-4M | $-10M | $-11M | $-11M | $-8M | $-8M | $-8M | $-8M | |
| Other Non-op | $-17.0K | $-58.0K | $-7.0K | $-33.0K | $-34.0K | $4.0K | $-53.0K | $35.0K | $10.0K | $-22.0K | $-73.0K | $-5.0K | $6.0K | $13.0K | $27.0K | $26.0K | |
| Pretax Income | $3M | $-908.0K | $-1M | $375.0K | $3M | $1M | $-3M | $2M | $-14M | $-11M | · | · | · | · | · | · | |
| Income Tax | $491.0K | $162.0K | $562.0K | $-455.0K | $508.0K | $195.0K | $0 | $0 | $0 | $0 | · | · | · | · | · | · | |
| Net Income | $3M | $-1M | $-2M | $830.0K | $3M | $1M | $-3M | $2M | $-14M | $-11M | $-11M | $-20M | $-7M | $-9M | $-8M | $-9M | |
| EPS (Basic) | $0.07 | $-0.03 | $-0.05 | $0.02 | $0.08 | $0.03 | $-0.06 | $0.06 | $-0.48 | $-0.45 | $-0.45 | $-1.14 | $-0.58 | $-0.77 | $-0.82 | $-0.96 | |
| EPS (Diluted) | $0.07 | $-0.03 | $-0.05 | $0.02 | $0.07 | $0.03 | $-0.06 | $0.06 | $-0.48 | $-0.45 | $-0.45 | $-1.14 | $-0.58 | $-0.77 | $-0.82 | $-0.96 | |
| Shares (Basic) | 35,891,915 | 36,021,210 | · | 36,383,277 | 35,786,813 | 34,642,641 | · | 28,738,307 | 28,364,731 | 24,887,180 | · | 17,863,078 | 12,463,665 | 11,622,384 | · | 9,215,786 | |
| Shares (Diluted) | 39,761,480 | 36,021,210 | · | 40,056,814 | 40,262,764 | 39,511,120 | · | 32,345,672 | 28,364,731 | 24,887,180 | · | 17,863,078 | 12,463,665 | 11,622,384 | · | 9,215,786 | |
| EBITDA | $2M | $-2M | · | $-388.0K | $3M | $642.0K | · | $-1M | $-4M | $-10M | · | $-11M | $-8M | $-8M | · | $-8M |
Balance Sheet
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $48M | $41M | $43M | $42M | $34M | $13M | $32M | $8M | $15M | $12M | $13M | $40M | $15M | $24M | $8M | $10M | |
| Receivables | $16M | $14M | $12M | $14M | $16M | $14M | $11M | $7M | $4M | $2M | $241.0K | $205.0K | $127.0K | $458.0K | $366.0K | $537.0K | |
| Inventory | $12M | $10M | $10M | $11M | $11M | $7M | $7M | $7M | $6M | $4M | $3M | $3M | $2M | $2M | $2M | $2M | |
| Prepaid Expense | $7M | $7M | $6M | $7M | $6M | $4M | $3M | $1M | $1M | $1M | $1M | $3M | $2M | $2M | $2M | $2M | |
| Current Assets | $131M | $120M | $120M | $121M | $113M | $84M | $74M | $29M | $31M | $34M | $37M | $46M | $19M | $29M | $16M | $18M | |
| PP&E (Net) | $4M | $4M | $3M | $3M | $2M | $2M | $2M | $2M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | |
| PP&E (Gross) | $9M | $9M | $8M | $8M | $8M | $7M | $7M | $7M | $7M | $6M | $6M | $6M | $6M | $6M | $6M | $6M | |
| Accum. Depreciation | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | |
| Total Assets | $137M | $125M | $124M | $124M | $117M | $87M | $77M | $32M | $34M | $36M | $39M | $48M | $21M | $31M | $18M | $20M | |
| Accounts Payable | $4M | $3M | $3M | $2M | $5M | $2M | $961.0K | $937.0K | $3M | $1M | $1M | $753.0K | $966.0K | $2M | $2M | $3M | |
| Accrued Liabilities | $9M | $7M | $8M | $6M | $6M | $4M | $5M | $6M | $4M | $4M | $5M | $5M | $6M | $7M | $5M | $5M | |
| Current Liabilities | $13M | $11M | $11M | $8M | $10M | $5M | $6M | $22M | $12M | $13M | $16M | $14M | $11M | $13M | $15M | $14M | |
| Capital Leases | $2M | $815.0K | $835.0K | $855.0K | $877.0K | $906.0K | $933.0K | $963.0K | $989.0K | $1M | $0 | · | · | · | · | · | |
| Other Non-current Liabilities | $327.0K | $615.0K | $628.0K | $582.0K | $578.0K | $896.0K | $766.0K | $563.0K | $632.0K | $962.0K | $840.0K | $1M | $1M | $1M | $1M | $1M | |
| Total Liabilities | $16M | $12M | $12M | $9M | $12M | $7M | $8M | $23M | $30M | $21M | $23M | $23M | $21M | $25M | $24M | $25M | |
| Long-term Debt | · | · | · | · | · | · | · | $2M | $4M | $7M | $10M | · | · | · | $16M | · | |
| Common Stock | $346.0K | $344.0K | $347.0K | $353.0K | $350.0K | $334.0K | $331.0K | $280.0K | $279.0K | $254.0K | $228.0K | $197.0K | $153.0K | $101.0K | $100.0K | $86.0K | |
| Paid-in Capital | $648M | $642M | $639M | $641M | $632M | $610M | $600M | $536M | $534M | $530M | $521M | $519M | $473M | $453M | $452M | $442M | |
| Retained Earnings | $-527M | $-530M | $-529M | $-527M | $-528M | $-530M | $-532M | $-528M | $-530M | $-516M | $-505M | $-494M | $-474M | $-466M | $-457M | $-447M | |
| AOCI | $258.0K | $571.0K | $575.0K | $875.0K | $592.0K | $381.0K | $82.0K | $11.0K | $8.0K | $157.0K | $135.0K | $-59.0K | $-64.0K | $-64.0K | $-83.0K | $-57.0K | |
| Stockholders' Equity | $121M | $113M | $111M | $115M | $105M | $80M | $69M | $9M | $4M | $15M | $16M | $25M | $-242.0K | $-13M | $-6M | $-5M | |
| Liabilities + Equity | $137M | $125M | $124M | $124M | $117M | $87M | $77M | $32M | $34M | $36M | $39M | $48M | $21M | $31M | $18M | $20M | |
| Shares Outstanding | 34,636,252 | 34,465,087 | 34,691,671 | 35,308,939 | 34,955,974 | 33,436,612 | 33,061,002 | 28,019,599 | 27,931,393 | 25,439,319 | 22,761,554 | 19,688,991 | 15,250,469 | 10,046,571 | 10,046,571 | 8,597,682 |
Cash Flow
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $6M | $857.0K | $8M | $5M | $7M | $2M | $-1M | $-4M | $-4M | $-10M | $-8M | $-9M | $-10M | $-4M | $-7M | $-5M | |
| CapEx | $503.0K | $570.0K | $550.0K | $459.0K | $398.0K | $140.0K | $229.0K | $216.0K | $101.0K | $13.0K | $19.0K | $-1.0K | $40.0K | $0 | $0 | $68.0K | |
| Investing Cash Flow | $-504.0K | $-571.0K | $-561.0K | $-466.0K | $-415.0K | $-25M | $-15M | $-697.0K | $10M | $5M | $-20M | $1.0K | $-40.0K | $0 | $0 | $-68.0K | |
| Stock Issued | $0 | $389.0K | $0 | $243.0K | $0 | $238.0K | $0 | $175.0K | $0 | $75.0K | $0 | $76.0K | $0 | $47.0K | $0 | $0 | |
| Stock Repurchased | $11.0K | $3M | · | · | $0 | $0 | · | · | · | · | · | · | · | · | · | · | |
| Net Stock Activity | · | $-3M | · | · | · | $238.0K | · | · | · | $75.0K | · | · | · | $47.0K | · | · | |
| Financing Cash Flow | $962.0K | $-2M | $-6M | $3M | $15M | $3M | $40M | $-2M | $-3M | $4M | $1.0K | $35M | $7.0K | $17M | $5M | $5M | |
| Net Change in Cash | $6M | $-2M | $2M | $7M | $22M | $-20M | $24M | $-6M | $3M | $-886.0K | $-28M | $26M | $-10M | $12M | $-2M | $-372.0K | |
| Taxes Paid | · | · | $228.0K | · | · | · | $0 | · | · | · | · | · | · | · | · | · | |
| Free Cash Flow | · | $287.0K | · | · | · | $2M | · | · | · | $-10M | · | · | · | $-4M | · | · |
Profitability
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 89.8% | 85.0% | · | 87.2% | 86.3% | 85.6% | · | 85.4% | 80.4% | 71.2% | · | 69.3% | 69.7% | 69.7% | · | · | |
| Operating Margin | 8.2% | -6.6% | · | -1.9% | 10.7% | 3.2% | · | -11.2% | -50.4% | -327.4% | · | -2432.3% | -1615.6% | -1394.5% | · | · | |
| Net Margin | 9.2% | -4.3% | · | 4.0% | 11.2% | 5.4% | · | 16.6% | -176.9% | -354.0% | · | -4686.6% | -1455.0% | -1507.5% | · | · | |
| Pretax Margin | 10.8% | -3.6% | · | 1.8% | 13.3% | 6.4% | · | · | · | · | · | · | · | · | · | · | |
| EBITDA Margin | 8.2% | -6.6% | · | -1.9% | 10.7% | 3.2% | · | -11.2% | -50.4% | -327.4% | · | -2432.3% | -1615.6% | -1394.5% | · | · | |
| ROA | 2.1% | -1.0% | · | 1.1% | 3.6% | 1.7% | · | 4.7% | -50.0% | -33.3% | · | -60.0% | -34.2% | -31.1% | · | -31.1% | |
| ROE | 2.4% | -1.1% | · | 1.4% | 4.9% | 2.2% | · | 11.2% | -695.8% | -1439.2% | · | -208.9% | 466.5% | 229.3% | · | -262.5% | |
| ROIC | 1.7% | -1.7% | · | -0.75% | 2.1% | 0.68% | · | · | · | · | · | · | · | · | · | · |
Liquidity & Solvency
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 9.8 | 11.2 | · | 15.1 | 10.9 | 16.0 | · | 1.3 | 2.6 | 2.5 | · | 3.3 | 1.8 | 2.2 | · | 1.3 | |
| Quick Ratio | 4.8 | 5.2 | · | 6.9 | 4.8 | 5.1 | · | 0.7 | 1.5 | 1.0 | · | 2.9 | 1.3 | 1.8 | · | 0.7 |
Efficiency
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.2 | 0.2 | · | 0.3 | 0.3 | 0.3 | · | 0.3 | 0.3 | 0.1 | · | 0.0 | 0.0 | 0.0 | · | · | |
| Inventory Turnover | 0.3 | 0.4 | · | 0.3 | 0.4 | 0.5 | · | 0.4 | 0.3 | 0.3 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | |
| Receivables Turnover | 1.8 | 1.8 | · | 2.0 | 2.5 | 2.6 | · | 3.1 | 4.0 | 3.1 | · | 1.2 | 1.8 | 1.9 | · | · |
Per Share
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $3.50 | $3.27 | · | $3.25 | $3.00 | $2.40 | · | $0.31 | $0.15 | $0.57 | · | $1.26 | $-0.02 | $-1.30 | · | $-0.61 | |
| Revenue / Share | $0.73 | $0.69 | · | $0.51 | $0.60 | $0.50 | · | $0.35 | $0.27 | $0.13 | · | $0.02 | $0.04 | $0.05 | · | · | |
| Cash Flow / Share | · | $0.02 | · | · | · | $0.06 | · | · | · | $-0.39 | · | · | · | $-0.37 | · | · | |
| Cash / Share | $1.37 | $1.20 | · | $1.18 | $0.98 | $0.38 | · | $0.30 | $0.53 | $0.46 | · | $2.06 | $0.95 | $2.41 | · | $1.14 | |
| EPS (TTM) | $0.01 | $0.01 | · | $0.06 | $0.10 | $-0.45 | · | $-1.32 | $-2.52 | $-2.62 | · | $-3.31 | $-3.13 | $-3.79 | · | $-3.95 |
Valuation (TTM)
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $95M | $90M | · | $80M | $70M | $54M | · | $23M | $12M | $5M | · | $2M | $3M | $3M | · | · | |
| Net Income TTM | $532.0K | $561.0K | · | $1M | $2M | $-14M | · | $-34M | $-56M | $-50M | · | $-45M | $-34M | $-37M | · | $-33M | |
| Market Cap | $436M | $320M | · | $380M | $475M | $426M | · | $253M | $234M | $121M | · | $80M | $89M | $58M | · | $28M | |
| P/E | 1259.0 | 928.0 | · | 179.2 | 136.0 | -28.3 | · | -6.8 | -3.3 | -1.8 | · | -1.2 | -1.9 | -1.5 | · | -0.8 | |
| P/S | 4.6 | 3.5 | · | 4.8 | 6.8 | 7.9 | · | 11.2 | 19.7 | 26.3 | · | 36.8 | 33.7 | 19.7 | · | · | |
| P/B | 3.6 | 2.8 | · | 3.3 | 4.5 | 5.3 | · | 29.5 | 55.8 | 8.3 | · | 3.2 | -367.4 | -4.4 | · | -5.2 | |
| P / Tangible Book | 3.6 | 2.8 | · | 3.3 | 4.5 | 5.3 | · | 29.5 | 55.8 | 8.3 | · | 3.2 | · | · | · | · | |
| P / Cash Flow | · | 373.2 | · | · | · | 193.2 | · | · | · | -12.7 | · | · | · | -13.5 | · | · | |
| Earnings Yield | 0.08% | 0.11% | · | 0.56% | 0.74% | -3.5% | · | -14.6% | -30.1% | -54.9% | · | -81.7% | -53.7% | -65.9% | · | -123.4% |
Most recent period on the left · null values shown as ·
Financial Statements Income statement, balance sheet, cash flow — annual, last 5 years
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Revenue | $85M | $37M | $2M | $3M | $4M |
| Gross Margin % | 86.2% | 83.4% | 69.2% | 74.8% | · |
| Operating Margin % | 0.77% | -33.4% | -1849.0% | -1245.0% | · |
| Net Income | $3M | $-26M | $-48M | $-37M | $-26M |
| Diluted EPS | $0.07 | $-0.93 | $-2.94 | $-4.12 | $-3.59 |
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Current Ratio | 10.9 | 12.0 | 2.3 | 1.1 | 5.2 |
| Quick Ratio | 5.0 | 7.0 | 0.8 | 0.5 | 3.8 |
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Free Cash Flow | $21M | $-19M | $-31M | $-25M | $-23M |
Institutional owners (13F) 139 filers · $243.2M total · As of June 30, 2026
Institutions that report holding this stock in their quarterly SEC Form 13F. Long positions only; a single filer may appear twice for separate option legs. Large offsetting put/call legs typically reflect market-making or hedged inventory, not directional conviction.
Holders
139
Value held
$243.2M
New positions
21
Exited positions
17
Institutional activity — Q2 2026 vs prior quarter
| New positions | Exited positions | Increased | Decreased | Net shares change |
|---|---|---|---|---|
| 21 (-10 vs prior Q) | 17 (-3 vs prior Q) | 48 (+10 vs prior Q) | 29 (-8 vs prior Q) | +1.1M |
Compared to Q1 2026. SEC Form 13F filings are due within 45 days of quarter-end plus a short buffer for late filers — quarters still inside that window are skipped in favor of the most recent fully-reported pair.
| Institution | Value | Shares | % of tracked 13F | Type |
|---|---|---|---|---|
| Rosalind Advisors, Inc. | $41,551,898 | 3,300,389 | 17.08% | Shares |
| BlackRock, Inc. | $34,078,638 | 2,706,802 | 14.01% | Shares |
| VANGUARD GROUP INC | $16,890,806 | 1,672,357 | 6.94% | Shares |
| VANGUARD CAPITAL MANAGEMENT LLC | $15,375,500 | 1,221,247 | 6.32% | Shares |
| Propel Bio Management, LLC | $10,971,681 | 871,460 | 4.51% | Shares |
| GEODE CAPITAL MANAGEMENT, LLC | $9,232,592 | 733,115 | 3.80% | Shares |
| STATE STREET CORP | $8,552,135 | 679,280 | 3.52% | Shares |
| ALGERT GLOBAL LLC | $7,311,114 | 580,708 | 3.01% | Shares |
| MILLENNIUM MANAGEMENT LLC | $7,130,611 | 566,371 | 2.93% | Shares |
| Divisadero Street Capital Management, LP | $6,292,432 | 499,796 | 2.59% | Shares |
| MORGAN STANLEY | $5,136,506 | 407,983 | 2.11% | Shares |
| ExodusPoint Capital Management, LP | $4,530,940 | 359,884 | 1.86% | Shares |
| Private Wealth Advisors, LLC | $3,913,765 | 310,863 | 1.61% | Shares |
| Simplify Asset Management Inc. | $3,333,454 | 264,770 | 1.37% | Shares |
| NORTHERN TRUST CORP | $3,174,040 | 252,108 | 1.30% | Shares |
| GOLDMAN SACHS GROUP INC | $3,151,429 | 250,312 | 1.30% | Shares |
| ADAR1 Capital Management, LLC | $2,825,007 | 224,385 | 1.16% | Shares |
| MARSHALL WACE, LLP | $2,756,745 | 218,963 | 1.13% | Shares |
| DIMENSIONAL FUND ADVISORS LP | $2,647,652 | 210,298 | 1.09% | Shares |
| KENNEDY CAPITAL MANAGEMENT LLC | $2,570,160 | 204,143 | 1.06% | Shares |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $2,435,510 | 193,448 | 1.00% | Shares |
| Ikarian Capital, LLC | $2,337,548 | 185,667 | 0.96% | Shares |
| VANGUARD FIDUCIARY TRUST CO | $2,290,159 | 181,903 | 0.94% | Shares |
| Nuveen, LLC | $2,286,281 | 181,595 | 0.94% | Shares |
| AQR CAPITAL MANAGEMENT LLC | $2,177,981 | 172,993 | 0.90% | Shares |
| CIBC WORLD MARKET INC. | $2,054,789 | 163,208 | 0.84% | Shares |
| Caption Management, LLC | $1,894,795 | 150,500 | 0.78% | Put option |
| Lane Generational LLC | $1,884,257 | 149,663 | 0.77% | Shares |
| HSBC HOLDINGS PLC | $1,705,848 | 135,600 | 0.70% | Shares |
| Man Group plc | $1,617,752 | 128,495 | 0.67% | Shares |
| Cubist Systematic Strategies, LLC | $1,562,514 | 145,350 | 0.64% | Shares |
| Diametric Capital, LP | $1,546,568 | 122,841 | 0.64% | Shares |
| Bank of New York Mellon Corp | $1,361,725 | 108,159 | 0.56% | Shares |
| BARCLAYS PLC | $1,359,090 | 107,950 | 0.56% | Shares |
| Caption Management, LLC | $1,259,000 | 100,000 | 0.52% | Call option |
| Capital Advisors Wealth Management, LLC | $1,170,870 | 93,000 | 0.48% | Shares |
| Jump Financial, LLC | $1,108,360 | 88,035 | 0.46% | Shares |
| Jefferies Financial Group Inc. | $1,057,308 | 83,980 | 0.43% | Shares |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $1,050,824 | 83,465 | 0.43% | Shares |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $1,022,308 | 81,200 | 0.42% | Call option |
| Stonepine Capital Management, LLC | $1,000,000 | 100,000 | 0.41% | Call option |
| Caption Management, LLC | $978,243 | 77,700 | 0.40% | Shares |
| Russell Investments Group, Ltd. | $851,813 | 67,658 | 0.35% | Shares |
| FOX RUN MANAGEMENT, L.L.C. | $776,526 | 61,678 | 0.32% | Shares |
| BANK OF AMERICA CORP /DE/ | $774,587 | 61,524 | 0.32% | Shares |
| Quantbot Technologies LP | $749,860 | 59,560 | 0.31% | Shares |
| D. E. Shaw & Co., Inc. | $728,885 | 57,894 | 0.30% | Shares |
| BNP PARIBAS FINANCIAL MARKETS | $725,864 | 57,654 | 0.30% | Shares |
| Creative Planning | $609,784 | 48,434 | 0.25% | Shares |
| UBS Group AG | $525,179 | 41,714 | 0.22% | Shares |
Activists & 5%+ owners 17 positions
Investors who filed SEC Schedule 13D — beneficial ownership above 5% with an intent to influence the issuer (activist stakes, board campaigns, M&A). Each row shows the most recent known state of that filer's position.
| Filer | Filed | Stake | Status | Purpose | Filing |
|---|---|---|---|---|---|
| Rosalind Advisors, Inc., SALAMON STEVEN A J, Aharon Gil, Rosalind Master Fund L.P., Rosalind Opportunities Fund I L.P. ×15 filings | Feb. 10, 2026 | 9.90% | Amendment | · | SEC |
| Undisclosed reporting person | Dec. 16, 2022 | · | Initial filing | Passive investment | SEC |
| Undisclosed reporting person | July 27, 2022 | · | Initial filing | Passive investment | SEC |
| Laddcap Value Partners LP S.S. or, Laddcap Value Associates LLC S.S. or, Laddcap Value Advisors LLC S.S. or, Robert Ladd S.S. or ×2 filings | Aug. 2, 2010 | · | Initial filing | · | SEC |
| Robert Ladd | Oct. 18, 2006 | · | Initial filing | Passive investment | SEC |
| Undisclosed reporting person | July 28, 2006 | · | Initial filing | Board campaign | SEC |
| Undisclosed reporting person | July 11, 2006 | · | Initial filing | · | SEC |
| Undisclosed reporting person | June 14, 2006 | · | Initial filing | · | SEC |
| Undisclosed reporting person | June 8, 2006 | · | Initial filing | · | SEC |
| Undisclosed reporting person | May 24, 2006 | · | Initial filing | · | SEC |
| Undisclosed reporting person | April 28, 2006 | · | Initial filing | · | SEC |
| Undisclosed reporting person | Jan. 10, 2006 | · | Initial filing | · | SEC |
| Undisclosed reporting person | Jan. 6, 2006 | · | Initial filing | · | SEC |
| Undisclosed reporting person | Dec. 14, 2005 | · | Initial filing | · | SEC |
| Undisclosed reporting person | Nov. 10, 2005 | · | Initial filing | Board campaign | SEC |
| Undisclosed reporting person | Oct. 24, 2005 | · | Initial filing | · | SEC |
| Undisclosed reporting person | Oct. 17, 2005 | · | Initial filing | Passive investment | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Company insiders 49 insiders · 13 officers · 17 directors
| Insider | Role | Last activity | Shares owned | Buys 12m | Sells 12m | Net 12m |
|---|---|---|---|---|---|---|
| Jennifer K. Simpson | President and CEO | May 8, 2020 C | 25,021 | 0 | 0 | $0 |
| Sandra Pennell | Chief Financial Officer | March 6, 2026 P | 77,018 | 1 | 0 | $50,018 |
| Barbra Keck | Chief Financial Officer, Secretary | May 8, 2020 C | 12,851 | 0 | 0 | $0 |
| Paul M Feinstein | Chief Financial Officer | Nov. 30, 2007 A | 3,375 | 0 | 0 | $0 |
| Martha S. Rook | CHIEF OPERATING OFFICER | Feb. 17, 2026 A | · | 0 | 0 | $0 |
| John Purpura | CHIEF OPERATING OFFICER | Feb. 8, 2023 A | 41,526 | 0 | 0 | $0 |
| HERSCHKOWITZ SAMUEL /FA/ | Chief Operating Officer | May 29, 2007 P | 160,375 | 0 | 0 | $0 |
| David L. Hoffman | GEN'L COUNSEL, CCO & SECY | Feb. 17, 2026 A | 74,330 | 0 | 0 | $0 |
| Kevin Muir | GM INTERVENTIONAL ONCOLOGY | Feb. 17, 2026 A | 18,582 | 0 | 0 | $0 |
| Vojo Vukovic | CHIEF MEDICAL OFFICER | Feb. 17, 2026 A | 168,882 | 0 | 0 | $0 |
| Johnny John | SVP CLINICAL DEV & MED AFFAIRS | Feb. 8, 2023 A | · | 0 | 0 | $0 |
| Anthony Dias | VP FINANCE | Feb. 8, 2023 A | · | 0 | 0 | $0 |
| Christine Padula | Interim Principal Accounting Officer | Sept. 1, 2021 A | · | 0 | 0 | $0 |
| Aharon Gil | Director | May 13, 2026 A | 3,413,468 | 0 | 0 | $0 |
| John Richard Sylvester | Director | May 13, 2026 A | 14,936 | 1 | 0 | $38,992 |
| Bridget A Martell | Director | May 13, 2026 A | · | 0 | 0 | $0 |
| Steven A J Salamon | Director | May 13, 2026 A | 3,413,468 | 0 | 0 | $0 |
| Roger G Stoll PHD | Director | May 23, 2024 A | 9,309 | 0 | 0 | $0 |
| Rosalind Advisors, Inc. | Director | Dec. 14, 2022 P | 459,315 | 0 | 0 | $0 |
| Marco Taglietti | Director | May 8, 2020 C | 6,000 | 0 | 0 | $0 |
| William Dodge Rueckert | Director | May 8, 2020 C | 6,014 | 0 | 0 | $0 |
| Simon Pedder | Director | Feb. 1, 2019 A | · | 0 | 0 | $0 |
| Laura A Philips | Director | July 23, 2015 P | 205,299 | 0 | 0 | $0 |
| Harold S Koplewicz | Director | June 10, 2015 A | 45,052 | 0 | 0 | $0 |
| Dennis Langer | Director | June 10, 2015 A | 20,000 | 0 | 0 | $0 |
| Jonathan Lewis | Director | June 30, 2008 A | 10,000 | 0 | 0 | $0 |
| Mark Corigliano | Director | April 16, 2007 M | 198,176 | 0 | 0 | $0 |
| Daniel Isdaner | Director | April 16, 2007 M | 253,668 | 0 | 0 | $0 |
| Elizabeth Czerepak | · | May 13, 2026 A | · | 0 | 0 | $0 |
| Gerard J Michel | · | March 2, 2026 P | 342,034 | 2 | 0 | $198,447 |
| Laura Brege | · | July 7, 2014 A | 11,678 | 0 | 0 | $0 |
| Tasos Konidaris | · | July 7, 2014 A | 11,678 | 0 | 0 | $0 |
| Gabriel Leung | · | July 7, 2014 A | 21,485 | 0 | 0 | $0 |
| Douglas G Watson | · | July 7, 2014 A | 136,664 | 0 | 0 | $0 |
| Graham G Miao | · | Nov. 14, 2013 A | 54,000 | 0 | 0 | $0 |
| Peter J Graham | · | Nov. 14, 2013 A | 15,000 | 0 | 0 | $0 |
| William M Appling | · | July 15, 2013 A | · | 0 | 0 | $0 |
| Krishna Kandarpa | · | March 11, 2013 A | 159,000 | 0 | 0 | $0 |
| Harold Mapes | · | March 11, 2013 A | 17,000 | 0 | 0 | $0 |
| Eamonn P Hobbs | · | March 11, 2013 A | 162,000 | 0 | 0 | $0 |
| Agustin V Gago | · | March 11, 2013 A | 80,944 | 0 | 0 | $0 |
| Robert Ladd | · | June 15, 2012 A | 69,534 | 0 | 0 | $0 |
| David Mcdonald | · | March 10, 2011 A | 47,706 | 0 | 0 | $0 |
| Pamela Reilly Contag | · | Dec. 1, 2010 A | 8,507 | 0 | 0 | $0 |
| Richard Taney | · | Dec. 10, 2009 A | 211,485 | 0 | 0 | $0 |
| Jason Andrew Rifkin | · | Oct. 12, 2009 A | · | 0 | 0 | $0 |
| KOLY M S /FA/ | · | Jan. 26, 2007 X | 775,360 | 0 | 0 | $0 |
| Victor Nevins | · | Oct. 12, 2006 M | 180,007 | 0 | 0 | $0 |
| VENKOL TRUST | · | Nov. 10, 2004 J | 892,649 | 0 | 0 | $0 |
Insiders from SEC Form 3/4/5 filings; net = open-market P/S only
ETF ownership Held by 16 ETFs
Weight reflects direct equity holdings (N-PORT) only; leveraged or derivative-based funds may hold additional swap exposure not shown.
| Fund | Weight | Units | As of | Source |
|---|---|---|---|---|
| IWC · iShares Trust | 0.11% | 97,206 SH | Sept. 11, 2026 | Daily |
| VTWV · VANGUARD SCOTTSDALE FUNDS | 0.02% | 21,358 SH | Aug. 19, 2026 | Daily |
| IWM · iShares Trust | 0.02% | 743,359 SH | Sept. 11, 2026 | Daily |
| OMFS · Invesco Exchange-Traded Self-Indexe… | 0.01% | 2,376 SH | Oct. 2, 2026 | Daily |
| RSSL · Global X Funds | 0.01% | 13,736 NS | July 31, 2026 | N-PORT |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0.01% | 165,177 SH | Aug. 19, 2026 | Daily |
| DFAS · Dimensional ETF Trust | 0.01% | 70,373 NS | July 31, 2026 | N-PORT |
| IWO · iShares Trust | 0.00% | 39,522 SH | Sept. 11, 2026 | Daily |
| DFSU · Dimensional ETF Trust | 0.00% | 3,297 NS | July 31, 2026 | N-PORT |
| ITOT · iShares Trust | 0.00% | 43,746 SH | Sept. 11, 2026 | Daily |
| DFAC · Dimensional ETF Trust | 0.00% | 12,489 NS | July 31, 2026 | N-PORT |
| VXF · VANGUARD INDEX FUNDS | 0.00% | 304,809 SH | Aug. 19, 2026 | Daily |
| VTI · VANGUARD INDEX FUNDS | 0.00% | 889,410 SH | Aug. 19, 2026 | Daily |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0.00% | 4,438 SH | Aug. 19, 2026 | Daily |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0.00% | 2,475 SH | Aug. 19, 2026 | Daily |
| IWN · iShares Trust | · | 228,409 SH | Sept. 11, 2026 | Daily |
DCTH Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside
rating · 12 analysts
BUY
Median target
$22.00
+45.4%
3 25.0%
Strong Buy
8 66.7%
Buy
1 8.3%
Hold
0 0.0%
Sell
0 0.0%
Strong Sell
12-Month Price Target
5 analysts · 2026-09-29Mean target $24.00 +58.6%
← Below all targets
Current price $15.13
Low$21.00
Mean$24.00
High$32.00
Peer comparison (GICS sub-industry) Key metrics vs sector peers
FY basis, prices as of each company's last fiscal year-end close.
| Ticker | Market Cap | P/E | Rev YoY | Net Margin | ROE | Gross Margin |
|---|---|---|---|---|---|---|
| DCTH | $350M | 144.3 | 129.1% | 3.2% | 2.5% | 86.2% |
| SSII | · | -94.7 | 105.7% | · | · | · |
| SENS | $228M | -3.3 | 56.9% | -196.0% | -88.7% | 44.7% |
| TCMD | $651M | 35.4 | 12.5% | 5.8% | 9.2% | 75.9% |
| SGHT | $424M | -10.7 | -3.1% | -49.7% | -57.4% | 86.2% |
| NPCE | $518M | -23.4 | 25.1% | -21.5% | -111.6% | 77.2% |
| SI | $295M | -3.1 | 49.6% | -85.3% | -129.1% | 76.5% |
| CARL | $329M | -5.8 | 85.9% | -58.7% | -375.2% | 75.3% |
| OFIX | $604M | -6.5 | 2.9% | -11.2% | -20.3% | 68.8% |
| ABT | $250.18B | 33.7 | 5.7% | 14.7% | 13.1% | · |
My Metrics Your personal watchlist — selected rows from Full Fundamentals
Pick the metrics that matter to you — click the + next to any row in Full Fundamentals above.
Your selection is saved and follows you across all tickers.
Source: SEC 10-Q filed Aug 6, 2026